Home > Neurology > MS Virtual 2020 > Neuromyelitis Optica Spectrum Disorders > Eculizumab reduces long-term relapse risk in AQP4-positive NMOSD

Eculizumab reduces long-term relapse risk in AQP4-positive NMOSD

MS Virtual 2020
Phase 3, PREVENT
Results of a long-term post-hoc analysis support the long-term effectiveness and safety of eculizumab monotherapy in aquaporin-4 (AQP4)-positive NMOSD. Over 90% of patients who had experienced 1 or 2 relapses in the year prior to the start of the PREVENT trial remained relapse-free through 192 weeks of eculizumab monotherapy [1]. PREVENT was a randomised, double-blind phase 3 trial in which eculizumab was associated with a significantly lower risk of relapse than placebo among patients with AQP4-positive NMOSD and was well tolerated [2]. The presented long-term results centred on the 33 patients who received eculizumab as monotherapy during PREVENT and/or its open-label extension (OLE), for a total of 85.3 patient-years (PY). In PREVENT, 1 of these 33 patients had experienced an adjudicated relapse versus 7 of 13 with pl...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on